Indoleamine 2,3-dioxygenase 1 promotes osteosarcoma progression by regulating tumor-derived exosomal miRNA hsa-miR-23a-3p
Background: Osteosarcoma (OS) is the most common primary malignant tumor originating in bone. Immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1) participates in tumor immune tolerance and promotes tumor progression, while the study of IDO1 in OS is limited.Methods: Immunohistochemistry an...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1194094/full |
| _version_ | 1797822551083188224 |
|---|---|
| author | Dan Yang Dan Yang Yinxian Chen Zhen Ning Tony He Yichen Wang Chenghui Ke Yi Luo Sun Wang Qichao Ma Mengjie Chen Qing Yang Ziming Zhang |
| author_facet | Dan Yang Dan Yang Yinxian Chen Zhen Ning Tony He Yichen Wang Chenghui Ke Yi Luo Sun Wang Qichao Ma Mengjie Chen Qing Yang Ziming Zhang |
| author_sort | Dan Yang |
| collection | DOAJ |
| description | Background: Osteosarcoma (OS) is the most common primary malignant tumor originating in bone. Immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1) participates in tumor immune tolerance and promotes tumor progression, while the study of IDO1 in OS is limited.Methods: Immunohistochemistry analysis was performed to test the expression of IDO1 and Ki67. The relationship between IDO1 or Ki67 positive count and clinical stage of the patient was analyzed. Laboratory test indexes including serum alkaline phosphatase (ALP), lactate dehydrogenase (LDH), white blood cell (WBC) count and C-reactive protein (CRP) at diagnosis of OS patients were collected. The relationship between positive count of IDO1 and Ki67 or laboratory test indexes was analyzed by Pearson’s correlation analysis. IDO1 stably overexpressed cell lines of these cells (MG63 OE, 143B OE and hFOB1.19 OE) were constructed and validated by Western blot and Elisa. Exosomes were isolated from conditioned culture media of these cells and were identified by Zetaview nanoparticle tracking analyzer. Next-generation sequencing was conducted to identify miRNAs enriched in exosomes. Differentially expressed miRNAs (DE miRNAs) were verified in clinical samples and cell lines by qPCR. Biological processes and cell components analysis of DE miRNAs was conducted by GO enrichment analysis using the protein interaction network database.Results: Immunosuppressive enzyme IDO1 was highly expressed in tumor tissues. 66.7% (6/9) of the tissues showed moderately or strongly positive immunostaining signal of IDO1, and 33.3% (3/9) were weakly positive. The expression of IDO1 was positively related to Ki67 and associated with prognostic-related clinical features of OS patients. Overexpression of IDO1 significantly affected the exosome-derived miRNA subsets from MG63, 143B and hFOB1.19 cells. A total of 1244 DE miRNAs were identified, and hsa-miR-23a-3p was further screened as key DE miRNA involved in the progression of OS. GO analysis of target genes of the DE miRNA results showed that target enrichment in the functions of immune regulation and tumor progression.Discussion: Our results indicate that IDO1 has the potential to promote the progression of OS that is related to miRNAs mediated tumor immunity. Targeting IDO1-mediated hsa-miR-23a-3p may be a potential therapeutic strategy for OS treatment. |
| first_indexed | 2024-03-13T10:09:44Z |
| format | Article |
| id | doaj.art-a6d2b46d32ec4001ac8b0fe06e5a6b5d |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-13T10:09:44Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-a6d2b46d32ec4001ac8b0fe06e5a6b5d2023-05-22T04:45:37ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-05-011410.3389/fphar.2023.11940941194094Indoleamine 2,3-dioxygenase 1 promotes osteosarcoma progression by regulating tumor-derived exosomal miRNA hsa-miR-23a-3pDan Yang0Dan Yang1Yinxian Chen2Zhen Ning Tony He3Yichen Wang4Chenghui Ke5Yi Luo6Sun Wang7Qichao Ma8Mengjie Chen9Qing Yang10Ziming Zhang11Department of Orthopedics, Shanghai Children’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaNHC Key Laboratory of Medical Embryogenesis and Developmental Molecular Biology & Shanghai Key Laboratory of Embryo and Reproduction Engineering, Shanghai, ChinaDepartment of Orthopedics, Shanghai Children’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaState Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, ChinaDepartment of Orthopedics, Shanghai Children’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaDepartment of Orthopedics, Shanghai Children’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaDepartment of Orthopedics, Shanghai Children’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaDepartment of Orthopedics, Shanghai Children’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaDepartment of Orthopedics, Shanghai Children’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaDepartment of Orthopedics, Shanghai Children’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaState Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, ChinaDepartment of Orthopedics, Shanghai Children’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaBackground: Osteosarcoma (OS) is the most common primary malignant tumor originating in bone. Immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1) participates in tumor immune tolerance and promotes tumor progression, while the study of IDO1 in OS is limited.Methods: Immunohistochemistry analysis was performed to test the expression of IDO1 and Ki67. The relationship between IDO1 or Ki67 positive count and clinical stage of the patient was analyzed. Laboratory test indexes including serum alkaline phosphatase (ALP), lactate dehydrogenase (LDH), white blood cell (WBC) count and C-reactive protein (CRP) at diagnosis of OS patients were collected. The relationship between positive count of IDO1 and Ki67 or laboratory test indexes was analyzed by Pearson’s correlation analysis. IDO1 stably overexpressed cell lines of these cells (MG63 OE, 143B OE and hFOB1.19 OE) were constructed and validated by Western blot and Elisa. Exosomes were isolated from conditioned culture media of these cells and were identified by Zetaview nanoparticle tracking analyzer. Next-generation sequencing was conducted to identify miRNAs enriched in exosomes. Differentially expressed miRNAs (DE miRNAs) were verified in clinical samples and cell lines by qPCR. Biological processes and cell components analysis of DE miRNAs was conducted by GO enrichment analysis using the protein interaction network database.Results: Immunosuppressive enzyme IDO1 was highly expressed in tumor tissues. 66.7% (6/9) of the tissues showed moderately or strongly positive immunostaining signal of IDO1, and 33.3% (3/9) were weakly positive. The expression of IDO1 was positively related to Ki67 and associated with prognostic-related clinical features of OS patients. Overexpression of IDO1 significantly affected the exosome-derived miRNA subsets from MG63, 143B and hFOB1.19 cells. A total of 1244 DE miRNAs were identified, and hsa-miR-23a-3p was further screened as key DE miRNA involved in the progression of OS. GO analysis of target genes of the DE miRNA results showed that target enrichment in the functions of immune regulation and tumor progression.Discussion: Our results indicate that IDO1 has the potential to promote the progression of OS that is related to miRNAs mediated tumor immunity. Targeting IDO1-mediated hsa-miR-23a-3p may be a potential therapeutic strategy for OS treatment.https://www.frontiersin.org/articles/10.3389/fphar.2023.1194094/fullosteosarcomaindoleamine 2,3-dioxygenase 1exosome miRNAstumor immunityimmunotherapeutic target |
| spellingShingle | Dan Yang Dan Yang Yinxian Chen Zhen Ning Tony He Yichen Wang Chenghui Ke Yi Luo Sun Wang Qichao Ma Mengjie Chen Qing Yang Ziming Zhang Indoleamine 2,3-dioxygenase 1 promotes osteosarcoma progression by regulating tumor-derived exosomal miRNA hsa-miR-23a-3p Frontiers in Pharmacology osteosarcoma indoleamine 2,3-dioxygenase 1 exosome miRNAs tumor immunity immunotherapeutic target |
| title | Indoleamine 2,3-dioxygenase 1 promotes osteosarcoma progression by regulating tumor-derived exosomal miRNA hsa-miR-23a-3p |
| title_full | Indoleamine 2,3-dioxygenase 1 promotes osteosarcoma progression by regulating tumor-derived exosomal miRNA hsa-miR-23a-3p |
| title_fullStr | Indoleamine 2,3-dioxygenase 1 promotes osteosarcoma progression by regulating tumor-derived exosomal miRNA hsa-miR-23a-3p |
| title_full_unstemmed | Indoleamine 2,3-dioxygenase 1 promotes osteosarcoma progression by regulating tumor-derived exosomal miRNA hsa-miR-23a-3p |
| title_short | Indoleamine 2,3-dioxygenase 1 promotes osteosarcoma progression by regulating tumor-derived exosomal miRNA hsa-miR-23a-3p |
| title_sort | indoleamine 2 3 dioxygenase 1 promotes osteosarcoma progression by regulating tumor derived exosomal mirna hsa mir 23a 3p |
| topic | osteosarcoma indoleamine 2,3-dioxygenase 1 exosome miRNAs tumor immunity immunotherapeutic target |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1194094/full |
| work_keys_str_mv | AT danyang indoleamine23dioxygenase1promotesosteosarcomaprogressionbyregulatingtumorderivedexosomalmirnahsamir23a3p AT danyang indoleamine23dioxygenase1promotesosteosarcomaprogressionbyregulatingtumorderivedexosomalmirnahsamir23a3p AT yinxianchen indoleamine23dioxygenase1promotesosteosarcomaprogressionbyregulatingtumorderivedexosomalmirnahsamir23a3p AT zhenningtonyhe indoleamine23dioxygenase1promotesosteosarcomaprogressionbyregulatingtumorderivedexosomalmirnahsamir23a3p AT yichenwang indoleamine23dioxygenase1promotesosteosarcomaprogressionbyregulatingtumorderivedexosomalmirnahsamir23a3p AT chenghuike indoleamine23dioxygenase1promotesosteosarcomaprogressionbyregulatingtumorderivedexosomalmirnahsamir23a3p AT yiluo indoleamine23dioxygenase1promotesosteosarcomaprogressionbyregulatingtumorderivedexosomalmirnahsamir23a3p AT sunwang indoleamine23dioxygenase1promotesosteosarcomaprogressionbyregulatingtumorderivedexosomalmirnahsamir23a3p AT qichaoma indoleamine23dioxygenase1promotesosteosarcomaprogressionbyregulatingtumorderivedexosomalmirnahsamir23a3p AT mengjiechen indoleamine23dioxygenase1promotesosteosarcomaprogressionbyregulatingtumorderivedexosomalmirnahsamir23a3p AT qingyang indoleamine23dioxygenase1promotesosteosarcomaprogressionbyregulatingtumorderivedexosomalmirnahsamir23a3p AT zimingzhang indoleamine23dioxygenase1promotesosteosarcomaprogressionbyregulatingtumorderivedexosomalmirnahsamir23a3p |